Gracell Biotechnologies I... (GRCL)
NASDAQ: GRCL
· Real-Time Price · USD
10.25
0.01 (0.05%)
At close: Feb 21, 2024, 10:00 PM
Gracell Biotechnologies Income Statement
Financials in CNY. Fiscal
year is
January - December.
| Fiscal Year | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 366K | n/a | n/a |
Cost of Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 366K | n/a | n/a |
Operating Income | -121.75M | -141.15M | -166.59M | -149.32M | -169.78M | -145.82M | -159.73M | -139.58M | -131.11M | -95.69M | -97.19M |
Interest Income | 9.91M | 5.27M | 14.63M | 15.14M | 3.58M | 2.7M | 2.5M | 3.46M | 2.98M | 1.73M | 932K |
Pretax Income | -67.61M | -146.92M | -151.71M | -130.67M | -171.93M | -146.31M | -158.58M | -128.59M | -129.28M | -96.22M | -97.67M |
Net Income | -67.63M | -146.93M | -151.73M | -130.69M | -172.21M | -145.13M | -156.01M | -128.59M | -129.28M | -96.22M | -97.67M |
Selling & General & Admin | 31.7M | 37.35M | 29.09M | 36.18M | 36.43M | 28.77M | 37.89M | 32M | 42.86M | 30.42M | 31.76M |
Research & Development | 90.05M | 103.8M | 137.51M | 113.14M | 133.35M | 117.06M | 121.84M | 107.58M | 88.62M | 65.27M | 65.43M |
Other Expenses | n/a | n/a | 630K | n/a | n/a | n/a | 144K | n/a | 733K | -48K | 128K |
Operating Expenses | 121.75M | 141.15M | 166.59M | 149.32M | 169.78M | 145.82M | 159.73M | 139.58M | 131.48M | 95.69M | 97.19M |
Interest Expense | 1.29M | 1.7M | 1.66M | 1.79M | 1.86M | 1.66M | 1.43M | 1.33M | 1.09M | 1.41M | 1.24M |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 121.75M | 141.15M | 166.59M | 149.32M | 169.78M | 145.82M | 159.73M | 139.58M | 131.48M | 95.69M | 97.19M |
Income Tax Expense | 13K | 10K | 16K | 22K | 279K | -1.18M | -2.57M | n/a | n/a | -322K | 303K |
Shares Outstanding (Basic) | 16.78M | 13.63M | 13.54M | 13.54M | 13.54M | 13.53M | 13.53M | 13.15M | 13.46M | 13.45M | 12.18M |
Shares Outstanding (Diluted) | 16.78M | 13.65M | 13.54M | 13.54M | 13.54M | 13.53M | 13.53M | 13.15M | 13.46M | 13.45M | 12.18M |
EPS (Basic) | -4.05 | -10.75 | -11.2 | -9.65 | -12.7 | -10.7 | -11.55 | -9.75 | -9.6 | -7.15 | -8 |
EPS (Diluted) | -4.05 | -10.75 | -11.2 | -9.65 | -12.7 | -10.7 | -11.55 | -9.75 | -9.6 | -7.15 | -8 |
EBITDA | -109.45M | -134.2M | -151.34M | -130.2M | -163.97M | -141.32M | -157.09M | -127.86M | -127.39M | -94M | -96.13M |
EBIT | -74.94M | -145.22M | -150.06M | -128.88M | -170.06M | -144.65M | -157.16M | -127.26M | -128.2M | -94.81M | -96.43M |
Depreciation & Amortization | 12.31M | 6.95M | 15.26M | 19.13M | 5.81M | 4.5M | 2.64M | 12.32M | 3.72M | 1.69M | 1.06M |